Advertisement
U.S. markets closed
Advertisement

Avalo Therapeutics, Inc. (AVTX)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
0.0651-0.0048 (-6.87%)
At close: 04:00PM EST
0.0659 +0.00 (+1.23%)
After hours: 07:59PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Short-term KST

Short-term KST

Performance Outlook
Previous Close0.0699
Open0.0622
Bid0.0646 x 900
Ask0.0657 x 800
Day's Range0.0622 - 0.0685
52 Week Range0.0610 - 6.0870
Volume22,502,848
Avg. Volume76,519,585
Market Cap12.524M
Beta (5Y Monthly)1.22
PE Ratio (TTM)N/A
EPS (TTM)-2.0000
Earnings DateNov 09, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est0.75
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for AVTX

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Avalo Therapeutics, Inc.
    SUPN: What does Argus have to say about SUPN?SUPERNUS PHARMACEUTICALS INC has an Investment Rating of SELL; a target price of $22.000000; an Industry Subrating of Low; a Management Subrating of Low; a Safety Subrating of Medium; a Financial Strength Subrating of Low; a Growth Subrating of Low; and a Value Subrating of High.
    Rating
    Fair Value
    Economic Moat
    4 days agoArgus Research
View more
  • GlobeNewswire

    Avalo Reports Third Quarter 2023 Financial Results and Provides Business Updates

    Successfully eliminated $35 million debt paving the way for future growth and innovationDivested AVTX-800 series for potential milestone payments of $45 million, fully focusing the pipeline on Avalo’s promising immunology assetsDisclosed improved cash of approximately $10.2 million as of September 30, 2023 WAYNE, Pa. and ROCKVILLE, Md., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), today announced business updates and financial results for the third quarter of 2023.

  • GlobeNewswire

    Avalo Completes Divestiture of AVTX-800 Series

    WAYNE, Pa. and ROCKVILLE, Md., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), today announced it has completed the divestiture of its rights, title and interest in, assets relating to AVTX-801 (D-galactose), AVTX-802 (D-mannose) and AVTX-803 (L-fucose) (collectively, the 800 Series) to AUG Therapeutics, LLC (AUG). The Company previously announced it entered into a purchase agreement with AUG to divest the 800 Series on September 12, 2023 (the Purchase Agreement). AUG

  • News Direct

    BestGrowthStocks.com Issues a Comprehensive Analysis of Avalo Therapeutics

    NEW YORK, NY / NewsDirect / September 27th, 2023 / Best Growth Stocks, a leading independent equity research and corporate access firm focused on finding and reporting on the best growth stocks uti...